

Opdivo Qvantig (nivolumab + hyaluronidase-nvhy) — CARECOST ESTIMATE · BILLING CHEAT SHEET

HCPCS J9289

Bristol Myers Squibb 300 mg / 2.5 mL and 600 mg / 5 mL single-dose vials (120 mg/mL) SC injection (3–5 min) abdomen or thigh

Reviewed: May 21, 2026 ASP: Q2 2026

HCPCS J9289 1 unit = 2 mg nivolumab	STD DOSE 300 units 600 mg q2w (450/q3w, 600/q4w)	MODIFIER JZ No waste at flat dose	ADMIN CPT 96401 Chemo SC (not 96372)	MEDICARE ASP+6% \$27.729 /unit · \$8,318.70/600 mg
---	--	---	--	--

CODES & NDC

HCPCS	J9289 — "Inj nivolumab 2 mg hyaluron" (perm. eff. 7/1/2025)
NDC (300 MG)	00003-3120-01 — 300 mg / 2.5 mL SDV
NDC (600 MG)	00003-6120-01 — 600 mg / 5 mL SDV
CONCENTRATION	120 mg nivolumab + 2,000 units hyaluronidase-nvhy per mL
IV SISTER	Opdivo (nivolumab IV) — HCPCS J9299 "Injection, nivolumab, 1 mg" — do NOT cross-bill
REV CODES (UB-04)	0636 drug + 0331 admin (+ 0250 pharmacy general where used)
BENEFIT	Medical (provider buy-and-bill)

ICD-10 — SC-APPROVED INDICATIONS

INDICATION	CODE
RCC (mono or + cabozantinib)	C64.x
Melanoma (mono, adjuvant)	C43.x
NSCLC mono (PD-L1 ≥1%) / adjuvant	C34.x
HNSCC	C00-C14, C32
Urothelial (mono / adjuvant)	C67.x
MSI-H / dMMR CRC	C18-C20 + biomarker
HCC (2L post-sorafenib)	C22.0
Esophageal / GEJ / gastric	C15.x, C16.x
Antineoplastic immunotherapy	Z51.12

DOSING (ADULT SOLID TUMORS ONLY)

DOSE	UNITS	VIALS (NO WASTE)
600 mg SC q2w	300	1 × 600 mg
900 mg SC q3w	450	1 × 600 mg + 1 × 300 mg
1200 mg SC q4w	600	2 × 600 mg

Pediatric and Yervoy (ipilimumab) combos NOT approved SC. Pediatric cHL, pediatric MSI-H, and any nivo + ipi regimen stay on IV J9299.

PAYER REQUIREMENTS (MAY 2026)

PAYER	PA	NOTES
UnitedHealthcare	Yes	Biomarker docs (PD-L1, MSI-H) per indication; office-preferred
Aetna (CPB 0892)	Yes	PD-L1 for NSCLC/HNSCC/gastric; SC steered out of HOPD
BCBS	Yes	Plan-specific; NCCN-aligned
Medicare (MAC LCDs)	No PA	FDA label + NCCN compendium

Biomarker: Same companion diagnostics as IV Opdivo — Dako 28-8 pharmDx PD-L1 (CPT 88360 / 88361), MMR IHC 88342, MSI 81301. Get results in hand BEFORE submitting PA.

ADMINISTRATION & MODIFIERS

CODE	WHEN
96401	Chemo SC/IM, non-hormonal anti-neoplastic — primary ; 1 unit per encounter
96372	Not appropriate — PD-1 SC uses chemo admin code
96413/96415	IV chemo — for J9299 (IV Opdivo) only

Worked example — 600 mg q2w: Draw 1 × 600 mg vial (NDC 00003-6120-01, 5 mL). Drug line: J9289 JZ × 300 units. Admin line: 96401 × 1. NDC qualifier N4 + 11-digit NDC + UoM ML + Qty 5 in 24A shaded.

MEDICARE REIMBURSEMENT (Q2 2026)

FIELD	VALUE
ASP + 6%	\$27.729 / unit (1 unit = 2 mg) (4/1 – 6/30/2026)
600 mg dose (q2w)	\$8,318.70 (300 units)
900 mg dose (q3w)	\$12,478.05 (450 units)
1200 mg dose (q4w)	\$16,637.40 (600 units)
Annualized (600 q2w × 26)	~\$216,286
Sequestration ~2%	Net ~ASP + 4.3%

SITE OF CARE

SETTING	POS	NOTES
Physician office	11	Preferred — SC fits without chair time
Ambulatory infusion	49	Preferred
Hospital outpatient	19/22	Disfavored — weak HOPD justification given 3–5 min admin
Patient home	12	Not currently covered for oncology checkpoint SC

PATIENT ASSISTANCE — BMS ACCESS SUPPORT

- **Phone:** 1-800-861-0048 (Mon–Fri 8a–8p ET) — benefits, PA, appeals
- **Web:** bmsaccesssupport.com/opdivoquantig
- **BMS Oncology Co-Pay:** commercial pts only; **excludes Medicare/Medicaid/federal**
- **BMSPAF:** free product for uninsured/underinsured (typ. ≤500% FPL) via Bristol Myers Squibb Patient Assistance Foundation 501(c)(3) — bmspaf.org
- **Independent foundations (Medicare):** PAN, HealthWell, CancerCare — verify open funds quarterly

TOP 3 DENIALS: (1) **Unit math** — billing at 1 unit = 1 mg instead of 2 mg (600 mg = 300 units, not 600). (2) **Wrong J-code** — J9299 (IV) instead of J9289 (SC). (3) **Wrong admin code** — 96372 instead of 96401.